## **INCYTE CORP**

ISIN: US45337C1027 WKN: 45337C102 Asset Class: Stock

Company 2024/05/21 22:00:00 Price 57, 40

Incyte 57.40

**Difference** 0.37%(0.21)


**Contact Details** 

INCYTE CORP. Tel: +1-302-498-6700

-- Fax: +

1801 Augustine Cut-Off Web: <a href="http://www.incyte.com">http://www.incyte.com</a>

19803 Wilmington <u>E-mail: -</u>



#### **Company Profile**

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

# Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	4,645,402,000		4,092,850,000		3,118,674,000	
Common stock capital		224,000		223,000		221,000
Fixed assets	2,176,919,000		1,790,696,000		1,855,056,000	
Equity capital of a company		5,189,837,000		4,370,119,000		3,770,004,000
Cash and cash equivalents	3,213,376,000		2,951,422,000		2,057,440,000	
Accrued liabilities		173,578,000		184,462,000		206,994,000
Other assets	-		-		-	
Current liabilities		1,240,379,000		1,157,077,000		854,308,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		392,105,000		356,350,000		349,418,000
Different income		-		-		-
Other liabilities		134,867,000		85,134,000		54,806,000
Total assets	6,822,321,000	6,822,321,000	5,883,546,000	5,883,546,000	4,973,730,000	4,973,730,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	2,524	2,324	2,094
Equity ratio	76.07%	74.28%	75.80%
Debt-equity ratio	31.46%	34.63%	31.93%

#### **Others**

	2023	2022	2021
Tax Expense Rate	28.36%	35.62%	-66.29%

# **INCYTE CORP**

ISIN: **US45337C1027** WKN: **45337C102** Asset Class: **Stock** 

Income statement			
	2023	2022	2021
Turnover	3,695,649,000	3,394,635,000	2,986,267,000
Net income	597,599,000	340,660,000	948,581,000
EBIT	769,992,073	489,345,796	526,678,310
Operating income before taxes	834,215,000	529,116,000	570,444,000
Cash Flow	496,487,000	969,941,000	749,488,000
Net interest income	-2,551,000	-2,666,000	-1,908,000
Research and development expenses	1,627,594,000	1,585,936,000	1,458,179,000
Income taxes	236,616,000	188,456,000	-378,137,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	1,347,360	1,344,124	1,312,303

## **Board of Directors**

Members of Management Board		
Edmund Harrigan	Member of Board of Directors	
Jacqualyn Fouse	Member of Board of Directors	
Katherine High	Member of Board of Directors	
Otis Brawley	Member of Board of Directors	
Susanne Antonie Schaffert	Member of Board of Directors	
Jean-Jacques Bienaimé	Member of Board of Directors	
Julian Baker	Member of Board of Directors	
Paul Clancy	Member of Board of Directors	
Hervé Hoppenot	Chairman of Managing Board	
Barry P. Flannelly	Member of Executive Committee	
Lothar H. Finke	Member of Executive Committee	
Steven H. Stein	Member of Executive Committee	
Christiana Stamoulis	Member of Executive Committee	
Denise Brashear	Member of Executive Committee	
Jonathan E. Dickinson	Member of Executive Committee	
Michael Morrissey	Member of Executive Committee	
Pablo J. Cagnoni	Member of Executive Committee	
Paula J. Swain	Member of Executive Committee	
Sheila A. Denton	Member of Executive Committee	
Vijay Iyengar	Member of Executive Committee	
Xiaozhao Wang	Member of Executive Committee	